Acxion ( Phentermine ) 15 Mg
Acxion ( Phentermine ) 15 Mg
6.4 mg, 15 mg and 30 mg
PHARMACEUTICAL FORM AND FORMULATION :
Each tablet contains:
Equivalent phentermine hydrochloride. . .6.4mg, 15mg and 30
Excipient c.b.p. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 tablet
THERAPEUTICAL INDICATIONS :
Anorexigene indicated as aid for the treatment of exogenous obesity with a Body Mass Index ( IMC ) > 30 kg / m2
or overweight with a BMI > 27 kg / m2 with certain associated comorbidities ( for example, high blood pressure, dyslipidemia, type 2 diabetes mellitus, sleep apnea, osteoarthritis ) associated with a low-calorie diet
IFA Acxion ® should not be co-administered with or for 14 days after administration of monoamine oxidase inhibitors, as hypertensive attacks may result. Phentermine should not be abused as a means of overcoming drowsiness or alertness. Hypersensitivity to the components of the formula. It should not be used in people with anorexia, insomnia, asthenia,
pregnancy and lactation or in children under 12 years of age. Psychotic personality, high blood pressure, elderly people, history of psychiatric illness, thyrotoxicosis, drug addiction or predisposition to alcohol abuse.
The recommended dose should not be exceeded, it is recommended to stop administration when the patient stops
lose weight. Like all medicines, it should be used with great caution in severe high blood pressure and cardiovascular disease, including arrhythmias. It has been reported that Acxion ( Phentermine ) 15 Mg may increase seizures in some epileptic patients: therefore, these types of patients should be closely monitored to adjust the dose or stop the drug. Prolonged use can lead to dependence on withdrawal syndrome when treatment is abruptly stopped.
RESTRICTIONS FOR USE DURING GROSSESSE AND FROZENING :
Although reproductive studies in rats and humans have indicated no risk to the fetus, IFA Acxion ® should not be used during pregnancy unless the potential benefits outweigh the potential risks. Considering that phentermine and / or its metabolites cross the placental barrier and are also excreted in breast milk, its administration to pregnant women or during lactation is not recommended. Some spontaneous isolated reports of birth defects have been reported, but none with a causal relationship with Phentermine.
SECONDARY AND ADVERSEQUISITIVE REACTIONS :
Systematic reports of adverse events with phentermine have not been identified and the frequency of adverse reactions is not defined. No serious adverse events have been reported in randomized controlled studies with phentermine, and given the number of patients studied, the rate could reach 15 per 1,000. Since phentermine is a sympathomimetic amine, side effects compatible with this class of medicines can be expected. Cases of cerebrovascular disease have been reported in people taking phentermine to lose weight, but as with all
case analysis reports, a causal relationship has not been established or presumed. The most common side effects include
High blood pressure, ischemic events, palpitations, tachycardia and primary pulmonary hypertension and regurgitating heart valve disease
Central nervous system
Dizziness, dysphoria, euphoria, headache, insomnia, overstimulation, agitation and psychosis
MEDICINAL INTERACTIONS AND OTHER GENERIES: IFA Acxion ® should not be administered with monoamine oxidase inhibitors ( IMAO ) or with general anesthetics, hypoglycemic drugs, including insulin, should be adjusted. IFA Acxion ® should not be administered to patients who are hypersensitive to appetite suppressants or other sympathomimetics, to patients with thyrotoxicosis, to people who are unstable or have a history of psychiatric illness, or patients with a history of drug addiction or with a predisposition to alcohol abuse.
PRECAUTIONS RELATING TO THE EFFECTS OF CANCEROGENESIS, MUTAGENESIS, ATTENUATION OF FERTILITY:
There are no long-term animal studies with Phentermine to assess carcinogenicity. No mutagenicity studies were known, with doses up to 100 mg. POSOLOGY AND ROUTE OF ADMINISTRATION
POSOLOGY AND ROUTE OF ADMINISTRATION : Oral.
The maximum recommended dose of Phentermine hydrochloride is 37.5 mg within 24 hours. Treatment should be started at the lowest possible dose ( 6.4 mg phentermine ) and increased only if the patient does not obtain clinically significant weight loss. Its administration is suggested 30 to 60 minutes before meals, with the last dose before 7:00 p.m. Patients should be followed at least once a month during the dose titration and at least every three months thereafter when receiving a stable dose.
The use of Phentermine as an adjuvant in the treatment of weight loss is recommended up to 36 weeks, continuously or intermittently ( 4 weeks with treatment and 4 weeks without treatment ).Considering that prolonged use can lead to dependence with syndrome
withdrawal at sudden interruption of treatment, to suspend treatment you will need to gradually reduce the dose until it is interrupted. IFA Acxion ® is not recommended for children under 12 years of age
or in the elderly.
EVENTS AND MANAGEMENT OF SURDOSAGE OR ACCIDENTAL INGESTION :
An acute overdose can have the following manifestations: agitation, tremors, hyperreflexy, rapid breathing, confusion, aggressiveness, hallucinations, panic states.
The management of acute intoxication is exclusively symptomatic based on gastric lavage and sedation by barbiturates. PRESENTATIONS :
Cardboard box of 10, 15, 30 or 90 tablets dosed at 6.4 mg, 15 mg and 30 mg.
PROTECTION LEGEND :
Exclusive literature for doctors Its sale requires an order that can be completed three times with a validity of six months
Its prolonged use even in therapeutic doses can lead to dependence.
Keep out of reach of children
Do not administer during pregnancy and lactation or in